Background: The NDM-1 carbapenemase has been identified in 2008 in Enterobacteriaceae. Since then, several reports have emphasized its rapid dissemination throughout the world. The spread of NDM carbapenemases involve several bla NDM gene variants associated with various plasmids among several Gram negative species.
Introduction
First identified in K. pneumoniae and E. coli isolates recovered from a patient previously hospitalized in India, NDM carbapenamase producers are of great concern worldwide [1] . NDM carbapenemases are metallo-ß-lactamases that have a very broad substrate profile, including carbapenems, but sparing monobactams. The bla NDM genes have been identified mostly in Enterobacteriaceae [2] , but also in Acinetobacter sp. [3] , Pseudomonas sp. [4] , and Vibrio sp. [5] . Although NDM-producers have been described worldwide, they are mainly recovered from patients who had a relationship with the Indian subcontinent [2] , and in some cases with the Balkan states [6] , and the Middle East [7] . Five NDM variants have been described, differing by several amino acid changes. A first variant, NDM-2, has been described in an A. baumannii clinical isolate in Germany from a patient native from Egypt [3] . NDM-4, NDM-5 and NDM-6 have been described from E. coli isolates from patients with history of hospitalization in India [8] [9] [10] .
NDM carbapenamase carriers are often multidrug-resistant as they co-express other antibiotic resistance genes conferring resistance to ß-lactams (such as other carbapenemase, extended spectrum ß-lactamase, or plasmid-mediated cephalosporinase genes) [2] or to other classes of antibiotics including aminoglycosides (16S rDNA methylases), quinolones and cyclines. These resistance determinants may be carried by identical plasmids and may be co-transferred. Several plasmids harbouring bla NDM genes have been sequenced [11] [12] [13] . Most of them belong to broad hostrange plasmids (IncA/C, IncL/M, IncFII, IncH) contributing to the dissemination of the bla NDM genes [14] .
Unlike other carbapenemase genes, the bla NDM genes have been described in E. coli that is by far the most frequent communityacquired human pathogen. In addition to India, E. coli isolates that produce NDM carbapenemase have also been reported in Canada [15] , Cameroon [16] , other Asian and European countries [17] .
Here, we have analysed an E. coli isolate harbouring a novel variant NDM-7 from a patient who had travelled to Burma.
Results and Discussion
A woman with repeated urinary tract infections travelled to Burma and was then hospitalized in France for surgery of prolapse. Two months later, a carbapenem-resistant E. coli COU isolate was recovered from the patient urine culture. Antibiogram determined by the disc diffusion technique and interpreted according to guidelines of the Clinical and Laboratory Standards Institute [18] , revealed that E. coli COU was resistant to penicillins, expanded-spectrum cephalosporins, and carbapenems. MICs of ß-lactams as shown in Table 1 , revealed that E. coli COU was resistant to ertapenem, imipenem, and meropenem. It was also resistant to fluoroquinolones, cotrimoxazole, to all tested aminoglycosides except amikacin, and to tetracycline. The isolate remained susceptible only to tigecycline (MIC of 0.38 mg/L), amikacin and chloramphenicol. The presence of a metallo-blactamase was assessed by using Etest MBL, which gave a positive result. E. coli COU belonged to the sequence type ST167, according to Multi Locus Sequence Typing [19] and to phylogenetic group A. ST167 clone belonged to complex ST10 that has previously been associated with bla CTX-M genes in Spain [20] .
PCR experiments using the whole DNA of E. coli COU as template and primers for detection of Ambler class A, class D and class B ß-lactamase genes identified bla NDM , bla CTX-M and bla OXA genes. No plasmid-mediated cephalosporinase, 16S rRNA methylase or qnr genes could be evidenced, contrary to what has been described for E. coli isolates harboring bla NDM genes [21] . DNA sequence analysis identified bla NDM-7 gene (GenBank accession number: JX412225) that had previously been reported once (GenBank accession number: JX262694), bla CTX-M-15 and bla OXA-1 genes. NDM-7 differed from NDM-1 by the substitution Met-154-Leu (as in NDM-4) [8] , and possessed an additional aspartateto-asparagine substitution at position 130 (Asp-130-Asn) ( Figure 1 ). Plasmid content of COU isolate revealed three different sized plasmids. A ca. 80-kb plasmid, pCOU, was successfully transferred to E. coli Az R J53 by conjugation and to E. coli DH10B by electroporation. The transformant TfCOU displayed a ß-lactam resistance pattern consistent with the expression of NDM-7 (Table 1) . No other antibiotic resistance marker was cotransferred, contrary to what is observed with many plasmids harboring bla NDM genes. Plasmid pCOU could not be characterized by PCR-based replicon typing aimed at identifying the main Inc group (FIA, FIB, FIC, HI2, I1-I, L/M, P, N, W, T, A/C, K, B/O, X, Y, F and FIIA) [22] . Upstream of the bla NDM-7 gene a fragment of insertion sequence ISAba125 was found, together with a bleomycin resistance gene downstream of the bla NDM-7 gene, as previously described for other bla NDM genes [12] (Figure 2, panel   D) . The immediate genetic environment of the bla NDM-7 gene was identical to that of other bla NDM genes identified from HongKong, India, and Bangladesh [11, 12, 25] .
NDM-4 has been described with increased hydrolytic activity toward carbapenems [8] . In order to evaluate and compare the spectrum of hydrolysis of NDM-7 and NDM-4 (differing by one amino acid substitution, [ figure 1 ]), the bla NDM-7 and bla NDM-4 genes were cloned using ZeroBlunt TOPO PCR cloning kit and then expressed in a same E. coli DH10B background. Recombinant strains harboring pNDM-7 and pNDM-4 were resistant or of reduced susceptibility to all ß-lactams except aztreonam. A crude ß-lactamase extract of recombinants strains were obtained and specific activities were determined for ertapenem and imipenem. No significant differences could be evidenced between isolates harbouring either pNDM-7 or pNDM-4 (data not shown). Therefore, the leucine residue at position 154 may explain the common property of extended hydrolytic activity toward carbapenems of both NDM-4 and NDM-7.
This study identified a novel NDM-type ß-lactamase, NDM-7. The strain has been isolated from a patient whose the only link with an endemic country was a travel to Burma. To our best knowledge, bla NDM genes have never been reported from this country and this case could further highlights the dissemination of NDM carbapenemases in Southeast Asia, after that in Tahiland [17] and Vietnam [23, 24] . This is also the first description of the bla NDM gene in E. coli isolate belonging to clonal complex ST-10, a successful clone for spread of bla CTX-M genes, as ST-131 clone.
Methodology
Bacterial isolates and plasmids E. coli COU was recovered from a urinary culture of a patient. Electrocompetent E. coli DH10B (Life Technologies, Saint-Aubin, France) was used as a recipient in electroporation experiments and sodium azide-resistant E. coli J53Az R was used as a recipient for conjugation experiments. The ZeroBlunt TOPO PCR vector was Table 1 . MICs of ß-lactams for E. coli COU, E. coli transformant (E. coli DH10B) TfCOU, recombinant plasmids pNDM-7 and pNDM-4 in E. coli DH10B and E. coli recipient strain DH10B. used for PCR cloning experiments (Life Technologies) [8] . Natural plasmids were extracted using Kieser extraction method or with Qiagen plasmid DNA maxi kit (Qiagen, Courtaboeuf, France).
Antimicrobial agents and MIC determinations
Antibiograms were determined by the disc diffusion method and MICs of ß-lactams and tigecycline were determined by Etest (bioMérieux, Marcy-L'Etoile, France) on Mueller-Hinton-Agar (Biorad, Marnes-la-Coquette, France) and interpreted as recommended by the Clinical and Laboratory Standards Institute (CLSI) [18] .
PCR amplification and sequencing
Total DNA from E. coli COU isolate was used as template for PCR reactions aimed at searching bla SHV , bla TEM , bla CTX-M , bla KPC , bla NDM , bla IMP , bla VIM , bla OXA-1/9 , plasmid-mediated cephalosporinase, qnr and 16S rRNA methylase genes. Both strands of the PCR products, were sequenced using laboratorydesigned primers with an automated sequencer (ABI PRISM 3100; Applied Biosystems). The genetic background of bla NDM gene was investigated by PCR mapping and by direct sequencing of pCOU using outward primers. PCR-based replicon typing of the main plasmid incompatibility groups reported in Enterobacteriaceae was performed as described [21] .
Multi Locus Sequence Typing
MLST with seven housekeeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) was performed according to Wirth et al. [19] . Allele sequences and sequence types (STs) were checked at the http:// mlst.ucc.ie web site.
Cloning experiments of bla NDM genes
Whole-cell DNAs were extracted as described [8] . The bla NDM genes from E. coli COU and E. coli I5 producing NDM-7 and NDM-4, respectively, were PCR amplified using the Pfu thermostable polymerase (Stratagene, Massy, France) and pre-NDM-for and pre-NDM-rev [8] , as previously described. These PCR fragments were then cloned into ZeroBlunt TOPO PCR vector (Life technologies), yielding plasmids pNDM-7 and pNDM-4. The sequences of the cloned PCR generated DNA fragments were confirmed by complete resequencing on both strands. Recombinant plasmids were transformed by electroporation into E. coli TOP10. Antibiotic-resistant colonies were selected onto Trypticase Soy (TS) agar plates containing imipenem (1 mg/ml).
Specific activity
ß-Lactamase extracts were obtained as described previously. The specific ß-lactamase activity of the extracts was measured by UV spectrophotometry (spectrophotometer ULTROSPEC 2000, Amersham Pharmacia Biotech, Orsay, France) as described previously [26] . The specific ß-lactamase activities were obtained with 100 mM imipenem and ertapenem as substrates. The total protein content was measured with the Bio-Rad DC protein assay kit (Bio-Rad, Marnes-la-Coquette, France).
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